Denali Therapeutics Inc. (DNLI)’s Trend Up, Especially After Today’s Strong Session

February 15, 2018 - By Vivian Currie

The stock of Denali Therapeutics Inc. (NASDAQ:DNLI) is a huge mover today! The stock increased 10.49% or $2.19 during the last trading session, reaching $23.12. About 110,886 shares traded. Denali Therapeutics Inc. (NASDAQ:DNLI) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 7 months positive chart setup for the $2.08 billion company. It was reported on Feb, 15 by We have $24.51 PT which if reached, will make NASDAQ:DNLI worth $124.98M more.

More notable recent Denali Therapeutics Inc. (NASDAQ:DNLI) news were published by: which released: “VC-backed Denali Therapeutics goes public” on December 08, 2017, also with their article: “The Funded: Denali Therapeutics sets IPO price range; 4 others raise rounds” published on November 29, 2017, published: “Takeda and Denali team up in neurodegenerative diseases” on January 05, 2018. More interesting news about Denali Therapeutics Inc. (NASDAQ:DNLI) were released by: and their article: “Drug maker led by Genenexers, and targeting Alzheimer’s, Parkinson’s and ALS …” published on November 14, 2017 as well as‘s news article titled: “Analyst: Denali Therapeutics’ Neuroscience Work Could Lead To Near-Term Upside” with publication date: January 03, 2018.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company has market cap of $2.08 billion. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It currently has negative earnings. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.